Aspire In Vitro Maturation Study (AIM)
2026年8月26日 更新者：Inception Fertility Research Institute, LLC
Pilot Study Assessing the Feasibility of CAPA-IVM in Participants With Good Ovarian Reserve
A study to assess the Capacitation - in-vitro maturation (CAPA-IVM) system as an option for patients with a good ovarian reserve to achieve pregnancy.
調査の概要
詳細な説明
CAPA-IVM is being evaluated for its feasibility as an In vitro maturation (IVM) system in US fertility clinics.
IVM is a laboratory process for maturing immature oocytes (eggs) outside of the body after egg retrieval.
Egg retrievals are performed without prior ovarian stimulation.
研究の種類
介入
入学 (推定)
40
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- Aspire Fertility Houston
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Signed Informed Consent Form to participate in this study voluntarily.
- Age 18-37 years at the time of starting the CAPA-IVM cycle.
- Body mass index (BMI) ≤38 kg/m2.
- Serum AMH levels greater than or equal to 3.5 ng/mL.
- Have an indication for IVM/IVF cycle.
- Have not received more than two previous treatments of IVM/IVF.
- Willing and able to comply with trial procedures, including oocyte pick-up from small follicles and to follow a CAPA-IVM cycle.
- Agree to culture all embryos to blastocyst stage, vitrify suitable blastocysts, and submit suitable blastocysts for PGT-A according to clinic protocol before determining transfer eligibility.
- Agree that only euploid CAPA-IVM-derived blastocysts will be eligible for transfer and that a single euploid blastocyst will be transferred per programmed FET cycle, unless a protocol-defined exception is prospectively justified by the investigator.
Exclusion Criteria:
- Prior ovarian surgery.
- Known uterine abnormalities (adenomyosis, leiomyoma (≥5 cm), bicornuate uterus, intrauterine adhesion) that would compromise successful pregnancy or live birth.
- Had received ovarian stimulation within the last 3 months for ovulation induction or IVF
- Had evidence of a very low oocyte maturation rate (oocyte maturation rate < 50% in any previous IVF or IVM cycle).
- For male partners: severe oligoasthenoteratozoospermia, requirement for retrograde ejaculation procedures or surgical sperm retrievals. Donor sperm is permitted.
- Known chromosomal abnormalities in participant or partner.
- Have herself or partner with acute urinary tract infection or sexually transmitted diseases.
- Have herself or partner a severe mental disorder, such as schizophrenia, bipolar affective disorder, or intellectual disability caused by mental disorders.
- Have a history of recurrent pregnancy loss defined as two or more clinical pregnancies without live birth.
- Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus that would preclude to conduct a CAPA-IVM cycle without ovarian stimulation or participation in this study.
- Any known clinically significant systemic disease (heart, liver, kidney or other organs) that would prevent or compromise pregnancy or participation in this study.
- Pregnancy or contraindication to pregnancy.
- Undiagnosed vaginal bleeding.
- Known drug or alcohol abuse or dependency for the participant or partner for the last 12 months.
- Current or past (3 months) smoking habit of 10 or more cigarettes per day.
- Had a recent exposure to teratogenic radiation, drugs or toxins which could still be active during the study period.
- Currently participating in another clinical trial or receiving an investigational medicinal product.
- Previous participation in this study.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：CAPA-IVM
Patients will undergo egg retrieval prior to in vitro maturation with CAPA-IVM system and subsequent frozen embryo transfer.
|
CAPA-IVM is a two-step IVM process to mature oocytes in the laboratory after egg retrieval.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Metaphase II rate
時間枠：Assessed approximately 40 hours after egg retrieval
|
The metaphase II (MII) rate is defined as the number of oocytes that reach MII stage of development divided by the number of cumulus-oocyte-complexes (COCs) placed into CAPA-IVM culture.
|
Assessed approximately 40 hours after egg retrieval
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of MII oocytes
時間枠：Assessed approximately 40 hours post egg retrieval
|
The number of oocytes that reach the metaphase II (MII) stage of development after CAPA-IVM culture
|
Assessed approximately 40 hours post egg retrieval
|
|
Fertilization rate
時間枠：Assessed 16-18 hours post fertilization
|
The fertilization rate is defined as the number of embryos that have 2 pro-nuclei post fertilization by intracytoplasmic sperm injection (ICSI)
|
Assessed 16-18 hours post fertilization
|
|
Number of blastocysts
時間枠：Assessed 5-7 days post fertilization
|
The number of embryos that make it to the blastocyst stage of development post fertilization
|
Assessed 5-7 days post fertilization
|
|
Number of blastocysts vitrified
時間枠：Assessed 5-7 days post fertilization
|
The number of embryos that are cryopreserved by vitrification post fertilization
|
Assessed 5-7 days post fertilization
|
|
Number of blastocysts submitted for PGT-A
時間枠：Assessed 5-7 days post fertilization
|
The number of embryos that are biopsied and samples sent for PGT-A testing
|
Assessed 5-7 days post fertilization
|
|
Number of euploid blastocysts
時間枠：Assessed 2-4 weeks post embryo biopsy
|
Number of embryos that had a euploid result from PGT-A testing
|
Assessed 2-4 weeks post embryo biopsy
|
|
Positive beta-hCG rate
時間枠：Assessed 9-11 days post embryo transfer
|
The number of patients with a serum QHCG level greater than 5 after embryo transfer divided by the total number of embryo transfers
|
Assessed 9-11 days post embryo transfer
|
|
Ongoing pregnancy rate
時間枠：Assessed approximately 10 weeks post embryo transfer
|
The number of patients who have an ongoing intrauterine pregnancy at the last study visit
|
Assessed approximately 10 weeks post embryo transfer
|
|
Live birth rate
時間枠：Assessed approximately 40 weeks post embryo transfer
|
Number of patients who had a live birth after embryo transfer
|
Assessed approximately 40 weeks post embryo transfer
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2026年8月26日
一次修了 (推定)
2028年2月1日
研究の完了 (推定)
2028年2月1日
試験登録日
最初に提出
2026年8月20日
QC基準を満たした最初の提出物
2026年8月26日
最初の投稿 (実際)
2026年8月27日
学習記録の更新
投稿された最後の更新 (実際)
2026年8月27日
QC基準を満たした最後の更新が送信されました
2026年8月26日
最終確認日
2026年8月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。